258 related articles for article (PubMed ID: 24006273)
41. The pendulum swings back: Screening for prostate cancer in 2018.
Thompson IM
Cancer; 2018 Jul; 124(13):2690-2692. PubMed ID: 29786846
[No Abstract] [Full Text] [Related]
42. Point: Impact of prostate-specific antigen velocity on management decisions and recommendations.
Loeb S; Carter HB
J Natl Compr Canc Netw; 2013 Mar; 11(3):281-5. PubMed ID: 23486454
[TBL] [Abstract][Full Text] [Related]
43. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
[TBL] [Abstract][Full Text] [Related]
44. Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations.
Zavaski ME; Meyer CP; Sammon JD; Hanske J; Gupta S; Sun M; Trinh QD
JAMA Intern Med; 2016 Apr; 176(4):546-7. PubMed ID: 26857148
[No Abstract] [Full Text] [Related]
45. Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder.
Aaronson DS; Redberg RF
JAMA Intern Med; 2016 Apr; 176(4):547-8. PubMed ID: 26856746
[No Abstract] [Full Text] [Related]
46. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
47. Prostate cancer: Risk factors - you find what you are looking for.
Wallis CJ; Satkunasivam R
Nat Rev Urol; 2017 Apr; 14(4):202-204. PubMed ID: 28031563
[No Abstract] [Full Text] [Related]
48. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
49. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience?
Baum M
Eur Urol; 2013 Oct; 64(4):540-1. PubMed ID: 23768633
[No Abstract] [Full Text] [Related]
50. Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.
Walsh EI; Turner EL; Lane JA; Donovan JL; Neal DE; Hamdy FC; Martin RM; ; ; ; ; ; ;
Trials; 2016 Oct; 17(1):497. PubMed ID: 27737692
[TBL] [Abstract][Full Text] [Related]
51. Prostate cancer: Prudent practice optimizes screening outcomes.
Auvinen A
Nat Rev Urol; 2016 Jul; 13(7):376-7. PubMed ID: 27215425
[No Abstract] [Full Text] [Related]
52. Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study.
Lundgren PO; Kjellman A; Norming U; Gustafsson O
J Urol; 2018 Jul; 200(1):82-88. PubMed ID: 29408619
[TBL] [Abstract][Full Text] [Related]
53. Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.
Smith SD; Birtwhistle R
Can Fam Physician; 2012 Sep; 58(9):e502-7. PubMed ID: 22972741
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
55. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
Loeb S
BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
[No Abstract] [Full Text] [Related]
56. Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
Roobol MJ; Kranse R; Bangma CH; Otto SJ; van der Kwast TH; Bokhorst LP; de Koning HJ; Schröder FH
Eur Urol; 2013 Oct; 64(4):541-3. PubMed ID: 23816273
[No Abstract] [Full Text] [Related]
57. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
Makovey I; Stephenson AJ; Haywood S
Curr Urol Rep; 2013 Jun; 14(3):168-73. PubMed ID: 23568623
[TBL] [Abstract][Full Text] [Related]
58. Strengthening evidence for active surveillance for prostate cancer.
Klotz L
Eur Urol; 2013 Jan; 63(1):108-10. PubMed ID: 23122665
[No Abstract] [Full Text] [Related]
59. Prostate cancer nomograms: a review of their use in cancer detection and treatment.
Caras RJ; Sterbis JR
Curr Urol Rep; 2014 Mar; 15(3):391. PubMed ID: 24452739
[TBL] [Abstract][Full Text] [Related]
60. Upgrading and upstaging at radical prostatectomy in the post-prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection?
Edmund L; Rotker KL; Lakis NS; Brito JM; Lepe M; Lombardo KA; Renzulli JF; Matoso A
Hum Pathol; 2017 Jan; 59():87-93. PubMed ID: 27720731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
